MX2023000198A - Inhibidores de atr y usos de estos. - Google Patents
Inhibidores de atr y usos de estos.Info
- Publication number
- MX2023000198A MX2023000198A MX2023000198A MX2023000198A MX2023000198A MX 2023000198 A MX2023000198 A MX 2023000198A MX 2023000198 A MX2023000198 A MX 2023000198A MX 2023000198 A MX2023000198 A MX 2023000198A MX 2023000198 A MX2023000198 A MX 2023000198A
- Authority
- MX
- Mexico
- Prior art keywords
- atr inhibitors
- compounds
- pharmaceutical compositions
- inhibitors
- atr
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
La presente divulgación se refiere a nuevos compuestos útiles como inhibidores de la cinasa ATR, así como a composiciones farmacéuticas que comprenden estos compuestos y métodos de tratamiento mediante la administración de estos compuestos o las composiciones farmacéuticas.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020100088 | 2020-07-03 | ||
| CN2020110396 | 2020-08-21 | ||
| CN2020134732 | 2020-12-09 | ||
| CN2020135604 | 2020-12-11 | ||
| PCT/CN2021/104232 WO2022002245A1 (en) | 2020-07-03 | 2021-07-02 | Atr inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000198A true MX2023000198A (es) | 2023-02-22 |
Family
ID=79317475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000198A MX2023000198A (es) | 2020-07-03 | 2021-07-02 | Inhibidores de atr y usos de estos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230339927A1 (es) |
| EP (1) | EP4175948A1 (es) |
| JP (1) | JP2023532303A (es) |
| KR (1) | KR20230035070A (es) |
| CN (1) | CN116134022A (es) |
| AU (1) | AU2021302146A1 (es) |
| BR (1) | BR112022024700A2 (es) |
| CA (1) | CA3185491A1 (es) |
| CO (1) | CO2023000858A2 (es) |
| IL (1) | IL299510A (es) |
| MX (1) | MX2023000198A (es) |
| TW (1) | TW202216701A (es) |
| WO (1) | WO2022002245A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023131234A1 (en) * | 2022-01-06 | 2023-07-13 | Shanghai Antengene Corporation Limited | Crystalline forms of an atr inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| US11690911B2 (en) * | 2017-08-04 | 2023-07-04 | Bayer Aktiengesellschaft | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors |
| RS65147B1 (sr) * | 2018-02-07 | 2024-02-29 | Wuxi Biocity Biopharmaceutics Co Ltd | Inhibitor atr i njegova primena |
| ES2954572T3 (es) * | 2018-09-07 | 2023-11-23 | Merck Patent Gmbh | Derivados de 5-morfolin-4-il-pirazolo[4,3-b]piridina |
-
2021
- 2021-07-02 US US18/014,178 patent/US20230339927A1/en active Pending
- 2021-07-02 TW TW110124500A patent/TW202216701A/zh unknown
- 2021-07-02 MX MX2023000198A patent/MX2023000198A/es unknown
- 2021-07-02 JP JP2022580916A patent/JP2023532303A/ja active Pending
- 2021-07-02 CN CN202180057399.5A patent/CN116134022A/zh active Pending
- 2021-07-02 KR KR1020237003732A patent/KR20230035070A/ko unknown
- 2021-07-02 BR BR112022024700A patent/BR112022024700A2/pt unknown
- 2021-07-02 AU AU2021302146A patent/AU2021302146A1/en active Pending
- 2021-07-02 EP EP21834378.8A patent/EP4175948A1/en active Pending
- 2021-07-02 IL IL299510A patent/IL299510A/en unknown
- 2021-07-02 CA CA3185491A patent/CA3185491A1/en active Pending
- 2021-07-02 WO PCT/CN2021/104232 patent/WO2022002245A1/en active Application Filing
-
2023
- 2023-01-26 CO CONC2023/0000858A patent/CO2023000858A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021302146A1 (en) | 2023-01-19 |
| EP4175948A1 (en) | 2023-05-10 |
| CN116134022A (zh) | 2023-05-16 |
| TW202216701A (zh) | 2022-05-01 |
| IL299510A (en) | 2023-02-01 |
| BR112022024700A2 (pt) | 2023-12-05 |
| JP2023532303A (ja) | 2023-07-27 |
| KR20230035070A (ko) | 2023-03-10 |
| CO2023000858A2 (es) | 2023-02-16 |
| WO2022002245A1 (en) | 2022-01-06 |
| CA3185491A1 (en) | 2022-01-06 |
| US20230339927A1 (en) | 2023-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2019014514A (es) | Compuestos para tratar la enfermedad de huntington. | |
| WO2018134685A3 (en) | Compounds | |
| MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| PH12016500531B1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| GEP20166484B (en) | Protein kinase inhibitors | |
| WO2019035863A8 (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | |
| AU2020281332A8 (en) | Dna-dependent protein kinase inhibitor | |
| MX2018007075A (es) | Compuestos policiclicos como inhibidores de tirosina quinasa de bruton. | |
| MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
| MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
| EA033238B1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
| MX2019009653A (es) | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos. | |
| MX2023003264A (es) | Inhibidores de cdk y su uso como productos fármaceuticos. | |
| AU2017269673A1 (en) | Pyridine dicarboxamide derivatives as bromodomain inhibitors | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| MX2021006156A (es) | Compuestos utiles en la terapia para el vih. | |
| MX2018007084A (es) | Inhibidores de la tirosina quinasa de bruton y metodos de su uso. | |
| PH12020550608A1 (en) | Pyrrole derivatives as acc inhibitors | |
| WO2016102672A3 (en) | Inhibitors of akt kinase | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
| TN2020000050A1 (en) | Novel phenylpyridine derivative and pharmaceutical composition containing same |